Mendus AB: Mendus secures manufacturing partner for establishing potential pivotal trial-stage and commercial production of DCP-001
yahoo.com
news
2022-10-18 06:00:00

Mendus AB

TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001



Mendus AB ('Mendus' publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced an agreement to enable the technology transfer for manufacturing of the company's lead development program DCP-001 with Minaris Regenerative Medicine GmbH ('Minaris'), a leading contract development and manufacturing service provider for the cell and gene therapy industry. DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial in ovarian cancer.
